LYEL
Lyell Immunopharma Inc
9.40$
-3.9%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -48.0% | -76.9% | +333.3% | +161.5% | -67.6% | -36.4% | +14.3% | +87.5% | -60.0% | -66.7% | +100.0% | – | |
| – | -0.9% | -0.7% | -2.4% | – | – | – | – | – | – | -2.7% | – | – | |
| – | – | – | +333.3% | +161.5% | -67.6% | -36.4% | +14.3% | +87.5% | -60.0% | -38,933.3% | – | – | |
| – | +4.1% | +3.7% | -6.7% | -1.9% | +23.2% | -10.7% | -19.8% | -19.2% | +85.3% | -29.9% | +8.0% | – | |
| – | -15.1% | +2.5% | -9.2% | -4.0% | +23.4% | -3.3% | -30.3% | +9.2% | -0.7% | -10.0% | +0.2% | – | |
| – | -1.3% | +1.4% | -7.3% | -1.9% | +298.0% | -71.5% | -17.8% | -21.0% | +64.5% | -28.5% | +8.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -0.6% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.